AFFILIATIONS
1 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States
10 NIH-National Human Genome Research Institute, Rockville, Maryland, United States
11 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States
12 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States
13 NIH-National Human Genome Research Institute, Rockville, Maryland, United States
14 Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States
ABSTRACT
The presence of pathogenic germline variants can promote early onset of clonal hematopoiesis (CH), such as in individuals with RUNX1-Familial Platelet Disorder (RUNX1-FPD) who harbor pathogenic germline heterozygous mutations in the gene encoding the RUNX1 transcription factor (TF). RUNX1-FPD patients present with an accelerated onset of CH and an increased lifetime risk of developing hematological malignancies. In turn, TET2-mutant clones are the second most-frequent observed in RUNX1-FPD patients with CH. Yet how somatic TET2 mutations cooperate with pathogenic germline RUNX1 variants to drive clonal expansions remains largely unknown. We hypothesize that TET2 and RUNX1 mutations cooperate via disruption of DNA methylation and chromatin remodeling, further impairing RUNX1 activity in RUNX1-FPD, increasing clonal fitness and risk of malignant transformation.
To test this, we seek to identify TET2-mutant-specific epigenetic features driving clonal fitness directly in RUNX1-FPD patient samples. To resolve the admixture of TET2-wildtype and TET2-mutant cells, we applied Genotyping of targeted loci with single-cell chromatin accessibility (GoT-ChA), an assay to simultaneously capture genotypes and chromatin accessibility from the same single cell, to bone marrow from RUNX1-FPD patients harboring TET2-mutant CH (n = 5 patients; 90,778 cells). Projection of TET2 genotypes showed an uneven distribution of mutated cells across hematopoietic differentiation. Surprisingly, we observed enrichment of TET2-mutant clones in common dendritic progenitors (P = 0.042) and a trend towards enrichment in natural killer (NK) cells. Conversely, we observed the expected decreased TET2-mutated cell abundance in T cell compartments (e.g. CD8 Effector, P = 0.005), demonstrating that TET2-mutant cells are unequally distributed across cell types in RUNX1-FPD patients.
The uneven distribution of TET2-mutated cells led us to ask if changes in observed cell type frequencies over time are driven by CH. We leveraged longitudinal sampling and mapped clonal identities for a RUNX1-FPD patient harboring somatic mutations in TET2 and SH2B3, a repressor of the JAK-STAT pathway. We found an expansion of the TET2 parental clone (+16.5% annual growth) and reduction of a subclone harboring the additional SH2B3 mutation (-4.0% annual growth) across 2 years, indicative of inter-clonal competition. Changes in cell type frequency positively correlated (P = 4.0 x 10-5, F-test) with the expansion of mutated cells within the cluster (e.g., hematopoietic stem cells (HSCs) and granulocyte–macrophage progenitors), signifying that the TET2 mutation confers cell type-specific proliferative advantages in RUNX1-FPD.
To assess TET2-mutant specific epigenetic features, we performed differential peak accessibility between TET2-wildtype and TET2-mutant HSCs. TET2-mutated HSCs exhibited open chromatin enriched in response to cytokine and leukocyte activation pathways. For example, we found increased accessibility at the CD86 locus, a cell-surface protein found to be upregulated in acute myeloid leukemia cell lines and associated with response to inflammation and stress when expressed in HSCs. Conversely, closed chromatin regions were associated with regulation of hematopoietic stem cell differentiation and blood coagulation pathways. For example, we found decreased accessibility at the HOXA5 locus, a master TF required for myeloid differentiation, previously found to be hypermethylated in myeloid blast crisis.
To define how TET2 mutations affect TF activity in HSCs, we performed differential TF motif accessibility. Notably, we found decreased RUNX1 motif accessibility in TET2-mutant HSCs (FDR = 8.75 x 10-4), consistent with enrichment of the RUNX1 motif in closed peaks (FDR = 2.29 x 10-5). These results are suggestive of a mechanism underlying positive epistatic interactions between the two mutations, where loss of TET2 disrupts RUNX1 function, potentially exacerbating RUNX1-FPD pathophysiology.
By capturing genotypes and chromatin accessibility simultaneously at the single cell level, we revealed CH clone-specific epigenetic features within RUNX1-FPD patient samples. Further research will aim at functional validation of epigenetic features underlying the fitness advantage of CH clones in RUNX1-FPD to nominate potential therapeutic vulnerabilities. Beyond RUNX1-FPD, our findings have the potential of contributing mechanistic and therapeutic insight to the CH field as a whole.